Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1838]

Identifying BRCA mutations for breast and ovarian cancer

Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus

Identifying BRCA mutations for breast and ovarian cancer ( Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus )

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2...

Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer ( Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA )

Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast...

Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras

Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )

Selective oestrogen receptor degraders as treatment for ER positive/HER2...

Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )

The challenges of treating breast cancer in Brazil

Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil

The challenges of treating breast cancer in Brazil ( Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil )

The importance of central pathology pCR review in an international multicenter...

Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )

SABCS 2019 highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2...

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )

Imaging for women who are high risk of breast cancer

Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA

Imaging for women who are high risk of breast cancer ( Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women...

Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer ( Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA )

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by...

Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC ( Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA )

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

More from ecancer